title: The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders.
abstract: Incretins are a group of gastrointestinal hormones detected both peripherally and in the central nervous system (CNS). Recent studies have documented multiple effects of incretins on brain structure and function. Research into the neurological effects of incretins has primarily focused on animal models of neurodegenerative disorders (e.g., Alzheimer's Disease, Huntington's and Parkinson's diseases). Mood disorders (e.g. bipolar disorder (BD), major depressive disorder (MDD)) are associated with similar alterations in brain structure and function, as well as a range of cognitive deficits (e.g. memory, learning, executive function). Brain abnormalities and cognitive deficits are also found in populations with metabolic disorders (e.g., diabetes mellitus Type 2). In addition, individuals with mood disorders often have co-morbid metabolic conditions, thus treatment strategies which can effectively treat both cognitive deficits and metabolic abnormalities represent a possible integrated treatment avenue. In particular, glucagon-like peptide-1 (GLP-1) and its more stable, longer-lasting analogues have been demonstrated to exert neuroprotective and anti-apoptotic effects, reduce beta-amyloid (Aβ) plaque accumulation, modulate long-term potentiation and synaptic plasticity, and promote differentiation of neuronal progenitor cells. In animal models of behaviour, treatment with GLP-1 receptor agonists has been demonstrated to improve measures of cognitive function including learning and memory, as well as reduce depressive behaviour. Available GLP-1 treatments also have a favourable metabolic profile which includes weight loss and reduced risk for hypoglycemia. Systematic evaluation of the effects of GLP-1 treatment in psychiatric populations who evince cognitive deficits represents a promising treatment avenue.
authors.affiliation: Department of Psychiatry, University of Toronto, Toronto, ON, Canada. roger.mcintyre@uhn.on.ca
authors.forename: Roger S
authors.initials: RS
authors.lastname: McIntyre
authors.forename: Alissa M
authors.initials: AM
authors.lastname: Powell
authors.forename: Oksana
authors.initials: O
authors.lastname: Kaidanovich-Beilin
authors.forename: Joanna K
authors.initials: JK
authors.lastname: Soczynska
authors.forename: Mohammad
authors.initials: M
authors.lastname: Alsuwaidan
authors.forename: Hanna O
authors.initials: HO
authors.lastname: Woldeyohannes
authors.forename: Ashley S
authors.initials: AS
authors.lastname: Kim
authors.forename: L Ashley
authors.initials: LA
authors.lastname: Gallaugher
mesh_terms: D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology*; D052216:Glucagon-Like Peptide 1 / Q000627:therapeutic use*; D006801:Humans; D019964:Mood Disorders / Q000150:complications*; D018696:Neuroprotective Agents / Q000627:therapeutic use*
chemical_list: D018696:Neuroprotective Agents; D052216:Glucagon-Like Peptide 1